Insights from 2023 WCLC


 

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Cemiplimab & Pembro"

103 views
October 9, 2023
Comments 0
Login to view comments. Click here to Login